Q1 2026 Clearpoint Neuro Inc Earnings Call Transcript
Key Points
- ClearPoint Neuro Inc (CLPT) achieved record revenue of $12.1 million for Q1 2026, marking a 43% growth compared to Q1 2025.
- The company's acquisition of IRRAS Holdings Inc contributed significantly to inorganic device growth, enhancing overall growth rate.
- ClearPoint Neuro Inc (CLPT) has over 60 active biopharma partners and more than 25 clinical trials across 15 disease indications, indicating strong industry collaboration.
- The company reported a gross margin increase to 64% in Q1 2026, up from 60% in Q1 2025, due to decreased inventory reserves.
- ClearPoint Neuro Inc (CLPT) is expanding its global presence, with more than 175 active sites using its technology, expected to surpass 200 by the end of 2026.
- Research and development costs increased by 34% to $4.5 million in Q1 2026, primarily due to higher personnel and development costs.
- Sales and marketing expenses rose by 75% to $6.7 million in Q1 2026, driven by additional personnel costs and increased travel expenses.
- General and administrative expenses increased by 22% to $5 million, mainly due to higher occupancy and personnel costs.
- The company experienced a cash reduction, with cash and cash equivalents totaling $35.6 million as of March 31, 2026, down from $45.9 million at the end of 2025.
- Operational cash burn was $8 million in Q1 2026, with expectations for a decrease in the coming quarters as the IRRAS integration completes.
Greetings, and welcome to the ClearPoint Neuro Inc first quarter 2026 financial results. (Operator Instructions) As a reminder, this conference is being recorded.
Comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, statements related to anticipated industry trends, the company's plans, prospects and strategies, both preliminary and projected.
Besides the total addressable markets or the market opportunity for the company's products and services; the company's expectations regarding the integration, performance and anticipated benefits of its recent acquisition of IRRAS Holdings Inc including operational efficiencies and the impact on the company's financial condition and results of operations.
The company's expectation for future development, regulatory approval, timing, commercialization and the market for cell and gene therapies and the anticipated adoption of the company's products and services for use in the delivery of gene and cell therapies, and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
